Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …

Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …

Background: The HAS-BLED, HEMORR 2 HAGES, ATRIA, and ORBIT scores are used to
predict bleeding risk in anticoagulated patients with atrial fibrillation (AF). Recently, these …

Let's end “real-world evidence” terminology usage: A study should be identified by its design -
Journal of Clinical Epidemiology Skip to Main Content Advertisement Submit Log in Register …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has placed an immense
burden on healthcare systems worldwide. There is intensive research targeted at better …

Background Several published studies have examined the association of coffee
consumption with atrial fibrillation (AF) risk, but their findings are still controversial …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …

Background Bleeding and thromboembolism prevention is important in patients with
nonvalvular atrial fibrillation receiving anticoagulants, including direct oral anticoagulants …